Search

Your search keyword '"Catherine Koering"' showing total 13 results

Search Constraints

Start Over You searched for: Author "Catherine Koering" Remove constraint Author: "Catherine Koering" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
13 results on '"Catherine Koering"'

Search Results

1. Differentiation is accompanied by a progressive loss in transcriptional memory

2. Supplementary Figure 2 from An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia

3. Supplementary Figure 1 from An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia

4. Data from An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia

5. Differentiation is accompanied by a progressive loss in transcriptional memory

6. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML)

7. Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML)

8. An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia

9. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML

10. HBx triggers either cellular senescence or cell proliferation depending on cellular phenotype

11. Prognostic Impact of ABCA3 Expression in Pediatric Acute Myeloid Leukemia

12. Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML)

13. TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

Catalog

Books, media, physical & digital resources